Plasma 1,25-dihydroxyvitamin d levels in patients receiving anticonvulsant drugs

William Jubiz; Mark R. Haussler; Toni A. McCain; Keith G. Tolman

doi:10.1210/jcem-44-4-617

Plasma 1,25-dihydroxyvitamin d levels in patients receiving anticonvulsant drugs

William Jubiz, Mark R. Haussler, Toni A. McCain, Keith G. Tolman

Basic Medical Sciences

Research output: Contribution to journal › Article › peer-review

99 Scopus citations

Abstract

Recent evidence has linked altered plasma vitamin D metabolite levels to the reported occurrence of hypocalcemia and other metabolic abnormalities in patients receiving anticonvulsant drugs. We have measured plasma levels of 25-hydroxyvitamin D (25-(OH)D) and 1,25-dihydroxyvitamin D (1,25-(OH)₂D) in institutionalized patients on diphenylhydantoin (Dilantin) and/or phenobarbital therapy. Values were compared with those obtained in institutionalized patients receiving no drugs and with normal ambulatory subjects. Although plasma 25-(OH)D levels were lower in the patients on drugs, a deficiency of 1,25-(OH)₂D, the tissue active metabolite of vitamin D, was not present. These results indicate that in patients taking anticonvulsant drugs, the serum calcium, phosphorus, alkaline phosphatase and parathyroid hormone (PTH) abnormalities are not caused by a defective formation of 1,25-(OH)₂D.

Original language	English (US)
Pages (from-to)	617-621
Number of pages	5
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	44
Issue number	4
DOIs	https://doi.org/10.1210/jcem-44-4-617
State	Published - Apr 1977

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1210/jcem-44-4-617

Fingerprint Dive into the research topics of 'Plasma 1,25-dihydroxyvitamin d levels in patients receiving anticonvulsant drugs'. Together they form a unique fingerprint.

Cite this

@article{509c138ff47941dca99fcb009cf85413,

title = "Plasma 1,25-dihydroxyvitamin d levels in patients receiving anticonvulsant drugs",

abstract = "Recent evidence has linked altered plasma vitamin D metabolite levels to the reported occurrence of hypocalcemia and other metabolic abnormalities in patients receiving anticonvulsant drugs. We have measured plasma levels of 25-hydroxyvitamin D (25-(OH)D) and 1,25-dihydroxyvitamin D (1,25-(OH)2D) in institutionalized patients on diphenylhydantoin (Dilantin) and/or phenobarbital therapy. Values were compared with those obtained in institutionalized patients receiving no drugs and with normal ambulatory subjects. Although plasma 25-(OH)D levels were lower in the patients on drugs, a deficiency of 1,25-(OH)2D, the tissue active metabolite of vitamin D, was not present. These results indicate that in patients taking anticonvulsant drugs, the serum calcium, phosphorus, alkaline phosphatase and parathyroid hormone (PTH) abnormalities are not caused by a defective formation of 1,25-(OH)2D.",

author = "William Jubiz and Haussler, {Mark R.} and McCain, {Toni A.} and Tolman, {Keith G.}",

year = "1977",

month = apr,

doi = "10.1210/jcem-44-4-617",

language = "English (US)",

volume = "44",

pages = "617--621",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "4",

}

TY - JOUR

T1 - Plasma 1,25-dihydroxyvitamin d levels in patients receiving anticonvulsant drugs

AU - Jubiz, William

AU - Haussler, Mark R.

AU - McCain, Toni A.

AU - Tolman, Keith G.

PY - 1977/4

Y1 - 1977/4

N2 - Recent evidence has linked altered plasma vitamin D metabolite levels to the reported occurrence of hypocalcemia and other metabolic abnormalities in patients receiving anticonvulsant drugs. We have measured plasma levels of 25-hydroxyvitamin D (25-(OH)D) and 1,25-dihydroxyvitamin D (1,25-(OH)2D) in institutionalized patients on diphenylhydantoin (Dilantin) and/or phenobarbital therapy. Values were compared with those obtained in institutionalized patients receiving no drugs and with normal ambulatory subjects. Although plasma 25-(OH)D levels were lower in the patients on drugs, a deficiency of 1,25-(OH)2D, the tissue active metabolite of vitamin D, was not present. These results indicate that in patients taking anticonvulsant drugs, the serum calcium, phosphorus, alkaline phosphatase and parathyroid hormone (PTH) abnormalities are not caused by a defective formation of 1,25-(OH)2D.

AB - Recent evidence has linked altered plasma vitamin D metabolite levels to the reported occurrence of hypocalcemia and other metabolic abnormalities in patients receiving anticonvulsant drugs. We have measured plasma levels of 25-hydroxyvitamin D (25-(OH)D) and 1,25-dihydroxyvitamin D (1,25-(OH)2D) in institutionalized patients on diphenylhydantoin (Dilantin) and/or phenobarbital therapy. Values were compared with those obtained in institutionalized patients receiving no drugs and with normal ambulatory subjects. Although plasma 25-(OH)D levels were lower in the patients on drugs, a deficiency of 1,25-(OH)2D, the tissue active metabolite of vitamin D, was not present. These results indicate that in patients taking anticonvulsant drugs, the serum calcium, phosphorus, alkaline phosphatase and parathyroid hormone (PTH) abnormalities are not caused by a defective formation of 1,25-(OH)2D.

UR - http://www.scopus.com/inward/record.url?scp=0017594321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017594321&partnerID=8YFLogxK

U2 - 10.1210/jcem-44-4-617

DO - 10.1210/jcem-44-4-617

M3 - Article

C2 - 849976

AN - SCOPUS:0017594321

VL - 44

SP - 617

EP - 621

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -